Global Antiviral Drugs Market Overview

Global Antiviral Drugs Market was valued at USD 58.48 Billion in 2021 and is expected to reach USD 80.66 Billion by the year 2028, at a CAGR of 4.7%.

Antiviral drugs are a class of medication that is used to kill or suppress the ability of a virus to replicate hence it prohibits the virus potential to proliferate and reproduce. Viruses are made of genetic material such as DNA or RNA which is alive when it is outside in the environment but gains its ability to reproduce and proliferate when it enters a susceptible host. In addition, antiviral drugs can prevent and protect individuals from getting viral infections or spreading the virus to others. Moreover, the development of antivirals is the outcome of newly acquired knowledge of the molecular and genetic activity of organisms letting us better apprehend the structure and function of viruses, chief advances in the techniques for finding novel drugs, and the stress placed on the medical sector to deal with the human immunodeficiency virus (HIV), the cause of acquired immunodeficiency syndrome is propelling the market growth in the period of forecast.

According to Statista, the global antiviral drug market is anticipated to reach 75 billion US dollars in 2027 from 52 billion US dollars in 2019. Additionally, there are many viruses which to date don't have antiviral drugs to treat the cause such as Rabies and HIV. According to WHO, 37.7 million people were living with HIV in 2020. Furthermore, to provide relief from viral diseases antiviral drugs are used, they significantly reduce the symptoms hence helps the infected individual to feel better, these factors are promoting the growth of the antiviral drugs market throughout the forecast.

COVID-19 Impact on Antiviral Drugs Market

The COVID-19 outbreak has significantly increased the demand for antiviral drugs globally. Moreover, COVID-19 disease has instigated governments to increase funding for research and development of antiviral drugs. COVID-19 has spurred the demand for antiviral drugs. Moreover, COVID-19 is an infectious viral disease of the upper respiratory tract hence it has a positive impact on the antiviral drug market. Furthermore, a government-imposed ban on transportation and the number of workers presents in antiviral drug manufacturing companies caused a small yet considerable impact on the production and supply chain.

Market Dynamics And Factors of Antiviral Drugs Market

Drivers:

The advantages of antiviral drugs are that they can cure some viral illnesses like hepatitis C or decrease the course of other viral illnesses like influenza. Antiviral drugs can be used to prevent the outbreak of certain viral illnesses like herpes. Moreover, characteristics of anti-viral drugs such as they can enter the cell infected with the virus and interfere with viral nucleic acid synthesis and thus restrict the virus ability to reproduce and proliferate in number thus, strengthening the growth of the anti-viral drugs market in the period o forecast. Furthermore, there has been a significant rise in the number of viral disease outbreaks in recent times hence to reduce future outbreaks there is a need for antiviral drugs hence strengthening the expansion of the antiviral drug market throughout the forecast.

Viral disease like smallpox is no longer a threat to the human population due to global vaccination programs. Furthermore, Polio caused by poliovirus is on the verge of extinction due to the wide-scale of antiviral drugs incorporated to prevent poliovirus from infecting healthy individuals. All these notable factors are promoting the use of antiviral drugs to prevent and eradicate viral diseases. Moreover, the increasing number of HIV, herpes, influenza, and other viral infections are driving the antiviral drug market. Furthermore, an increase in research and development activities for generating novel and advance formulations, such as vaccines, broad-spectrum antiviral drugs, and combination therapies to treat viral infection is propelling the antiviral drugs market.

Restraints:

Modern science technology has reached record height due to the research and development going on in this sector since the mid-20th century. Despite the rigorous research to find antivirals the arsenal of antivirals drugs remains dangerously small. Additionally, only about 100 antiviral drugs are available in the US market. Moreover, the lack of rapid diagnostic tests to identify viruses is hampering the antiviral drugs market in the period of forecast. Furthermore, the safety of antiviral drugs is a matter of concern. Moreover, a tremendous amount of money is utilized for manufacturing drugs which results in high pricing of antiviral drugs hence restraining the growth of the antiviral drugs market during the period of forecast. Antiviral drug resistance is a growing concern in immunocompromised individual populations, where ongoing viral replication and prolonged drug exposure results in the development of resistant strains. Moreover, WHO has reported cases of resistance to most antivirals including antiretroviral (ARV) drugs which are used to treat HIV thus hindering the antiviral drug market development in the span of the forecast. Furthermore, the growing trend of alternative medicines such as naturopathy and homeopathy are restraining the growth of the antiviral drug market throughout the forecast period.

Challenges:

To test the safety and efficiency of antiviral drugs, they are given to healthy individuals, however, sometimes it can cause adverse life-threatening situations thus trials on healthy individuals are the major challenge for the antiviral drug manufacturer. Moreover, urbanization has resulted in zoonosis (transfer of diseases from animals to humans) which has affected several economies worldwide. Furthermore, analyzing the disease-causing viral organism and producing antiviral drugs against it within a short period is one of the vital challenges for market players. In addition, on average to develop a novel antiviral drug takes around 10 to 15 years thus to reduce the time involved in research and developing effective antiviral drugs in a limited period is the biggest challenge for market players involved in antiviral drug manufacturing.

Opportunities:

The increasing number of viral infections and the growing demand for antiviral drugs is the major opportunity for market players. Moreover, several governments are investing huge funds in research and development to provide antiviral drugs to their population hence providing ample opportunities for market players. Developing broad-spectrum antiviral drugs with promising effects is a vital opportunity for market players.

Market Segmentation

Segmentation Analysis of Antiviral Drugs Market:

Based on Drug Action Mechanisms, Reverse Transcriptase Inhibitors are anticipated to have the highest share in the antiviral drugs market. The increasing number of HIV patients globally and the efficiency of these medicines to treat HIV infection are the key factors promoting the use of Reverse Transcriptase Inhibitors. Protease inhibitors are expected to have the second-highest share in the antiviral drug market owing to their ability to block the spread of HIV to uninfected cells.

Based on Application, the HIV segment is expected to dominate the antiviral drug market owing to the increasing cases of HIV patients. HIV followed by Hepatitis is estimated to have the second-largest share in the antiviral drug market owing to vaccination against Hepatitis A and Hepatitis B.

Based on Type, the antiviral drug market is segmented into branded and generic. The branded segment is estimated to dominate the antiviral drug market throughout the forecast owing to priorities given to branded drugs considering their effectiveness and almost negligible side effects. The generic segment is also expected to have significant growth in developing and underdeveloped countries owing to low prices and having almost the same efficacy as branded medicines.

Based on Age Group, the Geriatric segment is anticipated to lead the market owing to the increasing geriatric population and the high risk associated to contract the virus.

Regional analysis of Antiviral Drugs Market:

Depending on geography, the antiviral drug market is segmented into 5 regions North America, Middle East, and Africa, Asia­-Pacific, Europe, and South America.

North America is anticipated to dominate the antiviral drug market in the period of forecast owing to the enhanced and well-developed healthcare sector. Furthermore, the U.S. government is undertaking several measures including investment in infectious diseases programs and encouraging the R&D activities of innovative therapies to manage viral infections.

Asia-Pacific region is expected to grow at the fastest growth rate owing to the increasing prevalence and treatment rate of viral infections, developing healthcare sector, increasing number of research institutes, and increasing health awareness among people about infectious diseases.

Europe region is estimated to have a positive growth rate in the period of forecast. The well-developed healthcare sector, presence of major research institutes is propelling the antiviral drug market in this region.

Players Covered in Antiviral Drugs Market are:

• Gilead Sciences Inc (US)
• GlaxoSmithKline plc (UK)
• Johnson & Johnson Services Inc (US)
• AstraZeneca (UK)
• AbbVie Inc (US)
• Merck & Co Inc (US)
• Teva Pharmaceutical Industries Ltd (Israel) Regeneron Pharmaceuticals Inc (US)
• Bristol-Myers Squibb Company (US)
• Zydus Cadila (India)
• Cipla Inc (India)
• Prinston Pharmaceutical Inc (US)
• Hetero (India)
• Aurobindo Pharma (India)
• Apotex Inc (Canada)
• Mylan N.V. (US)
• Vir Biotechnology Inc (US) and others major key players.

Key Industry Development in Antiviral Drugs Market

• In September 2021, Gilead Sciences Inc declared the results of their phase 3 trial to evaluate the efficiency and safety of a three-day course of Veklury (Remdesivir). The results are remarkable as they showed positive effects for the treatment of COVID-19 in non-hospitalized patients who were at high risk for disease progression. The study involved 562 participants. These fresh data emphasize remdesivir's capability to aid the high-risk patient to recover before the advancement of the disease and stay out of the hospital.
• In March 2021, Vir Biotechnology in association with GlaxoSmithKline plc declared that an Independent Data Monitoring Committee (IDMC) suggested that the Phase 3 COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) trial evaluating VIR-7831, as monotherapy for the early treatment of COVID-19 in adults at high risk of hospitalization be stopped for enrolment due to confirmation of profound efficacy. The study involved the participation of 583 patients.
• In September 2021, Aurobindo Pharma received a patent from the Indian Patent Organization for its operation in the production of its antiviral drug valacyclovir, which is sold in the US and other countries under the trade name Valtrex. Aurobindo's invention is for the refined process for the production of the drug or pharmaceuticals acceptable salts. Valacyclovir hydrochloride is utilized in the treatment of viral infections such as genital herpes and herpes zoster in humans.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Type
 3.2 By Application
 3.3 By Age Group
 3.4 By Mechanism of Action

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Antiviral Drugs Market by Type
 5.1 Antiviral Drugs Market Overview Snapshot and Growth Engine
 5.2 Antiviral Drugs Market Overview
 5.3 Branded
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Branded: Grographic Segmentation
 5.4 Generics
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Generics: Grographic Segmentation

Chapter 6: Antiviral Drugs Market by Application
 6.1 Antiviral Drugs Market Overview Snapshot and Growth Engine
 6.2 Antiviral Drugs Market Overview
 6.3 Influenza
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Influenza: Grographic Segmentation
 6.4 HIV
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 HIV: Grographic Segmentation
 6.5 Hepatitis
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2016-2028F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Hepatitis: Grographic Segmentation
 6.6 Herpes Simplex Virus {HSV}
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size (2016-2028F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Herpes Simplex Virus {HSV}: Grographic Segmentation
 6.7 Coronavirus Infection
  6.7.1 Introduction and Market Overview
  6.7.2 Historic and Forecasted Market Size (2016-2028F)
  6.7.3 Key Market Trends, Growth Factors and Opportunities
  6.7.4 Coronavirus Infection: Grographic Segmentation
 6.8 Human Papillomavirus
  6.8.1 Introduction and Market Overview
  6.8.2 Historic and Forecasted Market Size (2016-2028F)
  6.8.3 Key Market Trends, Growth Factors and Opportunities
  6.8.4 Human Papillomavirus: Grographic Segmentation
 6.9 Others
  6.9.1 Introduction and Market Overview
  6.9.2 Historic and Forecasted Market Size (2016-2028F)
  6.9.3 Key Market Trends, Growth Factors and Opportunities
  6.9.4 Others: Grographic Segmentation

Chapter 7: Antiviral Drugs Market by Age Group
 7.1 Antiviral Drugs Market Overview Snapshot and Growth Engine
 7.2 Antiviral Drugs Market Overview
 7.3 Adult
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size (2016-2028F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Adult: Grographic Segmentation
 7.4 Pediatric
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size (2016-2028F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Pediatric: Grographic Segmentation

Chapter 8: Antiviral Drugs Market by Mechanism of Action
 8.1 Antiviral Drugs Market Overview Snapshot and Growth Engine
 8.2 Antiviral Drugs Market Overview
 8.3 DNA Polymerase Inhibitors
  8.3.1 Introduction and Market Overview
  8.3.2 Historic and Forecasted Market Size (2016-2028F)
  8.3.3 Key Market Trends, Growth Factors and Opportunities
  8.3.4 DNA Polymerase Inhibitors: Grographic Segmentation
 8.4 Reverse Transcriptase Inhibitors
  8.4.1 Introduction and Market Overview
  8.4.2 Historic and Forecasted Market Size (2016-2028F)
  8.4.3 Key Market Trends, Growth Factors and Opportunities
  8.4.4 Reverse Transcriptase Inhibitors: Grographic Segmentation
 8.5 Protease Inhibitors
  8.5.1 Introduction and Market Overview
  8.5.2 Historic and Forecasted Market Size (2016-2028F)
  8.5.3 Key Market Trends, Growth Factors and Opportunities
  8.5.4 Protease Inhibitors: Grographic Segmentation
 8.6 Neuraminidase Inhibitors
  8.6.1 Introduction and Market Overview
  8.6.2 Historic and Forecasted Market Size (2016-2028F)
  8.6.3 Key Market Trends, Growth Factors and Opportunities
  8.6.4 Neuraminidase Inhibitors: Grographic Segmentation
 8.7 Integrase inhibitors
  8.7.1 Introduction and Market Overview
  8.7.2 Historic and Forecasted Market Size (2016-2028F)
  8.7.3 Key Market Trends, Growth Factors and Opportunities
  8.7.4 Integrase inhibitors: Grographic Segmentation
 8.8 Attachment inhibitors
  8.8.1 Introduction and Market Overview
  8.8.2 Historic and Forecasted Market Size (2016-2028F)
  8.8.3 Key Market Trends, Growth Factors and Opportunities
  8.8.4 Attachment inhibitors: Grographic Segmentation
 8.9 Others
  8.9.1 Introduction and Market Overview
  8.9.2 Historic and Forecasted Market Size (2016-2028F)
  8.9.3 Key Market Trends, Growth Factors and Opportunities
  8.9.4 Others: Grographic Segmentation

Chapter 9: Company Profiles and Competitive Analysis
 9.1 Competitive Landscape
  9.1.1 Competitive Positioning
  9.1.2 Antiviral Drugs Sales and Market Share By Players
  9.1.3 Industry BCG Matrix
  9.1.4 Ansoff Matrix
  9.1.5 Antiviral Drugs Industry Concentration Ratio (CR5 and HHI)
  9.1.6 Top 5 Antiviral Drugs Players Market Share
  9.1.7 Mergers and Acquisitions
  9.1.8 Business Strategies By Top Players
 9.2 GILEAD SCIENCES INC
  9.2.1 Company Overview
  9.2.2 Key Executives
  9.2.3 Company Snapshot
  9.2.4 Operating Business Segments
  9.2.5 Product Portfolio
  9.2.6 Business Performance
  9.2.7 Key Strategic Moves and Recent Developments
  9.2.8 SWOT Analysis
 9.3 GLAXOSMITHKLINE PLC
 9.4 JOHNSON & JOHNSON SERVICES INC
 9.5 ASTRAZENECA
 9.6 ABBVIE INC
 9.7 MERCK & CO INC
 9.8 TEVA PHARMACEUTICAL INDUSTRIES LTD
 9.9 REGENERON PHARMACEUTICALS INC
 9.10 BRISTOL-MYERS SQUIBB COMPANY
 9.11 ZYDUS CADILA
 9.12 CIPLA INC
 9.13 PRINSTON PHARMACEUTICAL INC
 9.14 HETERO
 9.15 AUROBINDO PHARMA
 9.16 APOTEX INC
 9.17 MYLAN N.V.
 9.18 VIR BIOTECHNOLOGY INC.
 9.19 OTHER MAJOR PLAYERS

Chapter 10: Global Antiviral Drugs Market Analysis, Insights and Forecast, 2016-2028
 10.1 Market Overview
 10.2 Historic and Forecasted Market Size By Type
  10.2.1 Branded
  10.2.2 Generics
 10.3 Historic and Forecasted Market Size By Application
  10.3.1 Influenza
  10.3.2 HIV
  10.3.3 Hepatitis
  10.3.4 Herpes Simplex Virus {HSV}
  10.3.5 Coronavirus Infection
  10.3.6 Human Papillomavirus
  10.3.7 Others
 10.4 Historic and Forecasted Market Size By Age Group
  10.4.1 Adult
  10.4.2 Pediatric
 10.5 Historic and Forecasted Market Size By Mechanism of Action
  10.5.1 DNA Polymerase Inhibitors
  10.5.2 Reverse Transcriptase Inhibitors
  10.5.3 Protease Inhibitors
  10.5.4 Neuraminidase Inhibitors
  10.5.5 Integrase inhibitors
  10.5.6 Attachment inhibitors
  10.5.7 Others

Chapter 11: North America Antiviral Drugs Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Type
  11.4.1 Branded
  11.4.2 Generics
 11.5 Historic and Forecasted Market Size By Application
  11.5.1 Influenza
  11.5.2 HIV
  11.5.3 Hepatitis
  11.5.4 Herpes Simplex Virus {HSV}
  11.5.5 Coronavirus Infection
  11.5.6 Human Papillomavirus
  11.5.7 Others
 11.6 Historic and Forecasted Market Size By Age Group
  11.6.1 Adult
  11.6.2 Pediatric
 11.7 Historic and Forecasted Market Size By Mechanism of Action
  11.7.1 DNA Polymerase Inhibitors
  11.7.2 Reverse Transcriptase Inhibitors
  11.7.3 Protease Inhibitors
  11.7.4 Neuraminidase Inhibitors
  11.7.5 Integrase inhibitors
  11.7.6 Attachment inhibitors
  11.7.7 Others
 11.8 Historic and Forecast Market Size by Country
  11.8.1 U.S.
  11.8.2 Canada
  11.8.3 Mexico

Chapter 12: Europe Antiviral Drugs Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Type
  12.4.1 Branded
  12.4.2 Generics
 12.5 Historic and Forecasted Market Size By Application
  12.5.1 Influenza
  12.5.2 HIV
  12.5.3 Hepatitis
  12.5.4 Herpes Simplex Virus {HSV}
  12.5.5 Coronavirus Infection
  12.5.6 Human Papillomavirus
  12.5.7 Others
 12.6 Historic and Forecasted Market Size By Age Group
  12.6.1 Adult
  12.6.2 Pediatric
 12.7 Historic and Forecasted Market Size By Mechanism of Action
  12.7.1 DNA Polymerase Inhibitors
  12.7.2 Reverse Transcriptase Inhibitors
  12.7.3 Protease Inhibitors
  12.7.4 Neuraminidase Inhibitors
  12.7.5 Integrase inhibitors
  12.7.6 Attachment inhibitors
  12.7.7 Others
 12.8 Historic and Forecast Market Size by Country
  12.8.1 Germany
  12.8.2 U.K.
  12.8.3 France
  12.8.4 Italy
  12.8.5 Russia
  12.8.6 Spain
  12.8.7 Rest of Europe

Chapter 13: Asia-Pacific Antiviral Drugs Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Type
  13.4.1 Branded
  13.4.2 Generics
 13.5 Historic and Forecasted Market Size By Application
  13.5.1 Influenza
  13.5.2 HIV
  13.5.3 Hepatitis
  13.5.4 Herpes Simplex Virus {HSV}
  13.5.5 Coronavirus Infection
  13.5.6 Human Papillomavirus
  13.5.7 Others
 13.6 Historic and Forecasted Market Size By Age Group
  13.6.1 Adult
  13.6.2 Pediatric
 13.7 Historic and Forecasted Market Size By Mechanism of Action
  13.7.1 DNA Polymerase Inhibitors
  13.7.2 Reverse Transcriptase Inhibitors
  13.7.3 Protease Inhibitors
  13.7.4 Neuraminidase Inhibitors
  13.7.5 Integrase inhibitors
  13.7.6 Attachment inhibitors
  13.7.7 Others
 13.8 Historic and Forecast Market Size by Country
  13.8.1 China
  13.8.2 India
  13.8.3 Japan
  13.8.4 Singapore
  13.8.5 Australia
  13.8.6 New Zealand
  13.8.7 Rest of APAC

Chapter 14: Middle East & Africa Antiviral Drugs Market Analysis, Insights and Forecast, 2016-2028
 14.1 Key Market Trends, Growth Factors and Opportunities
 14.2 Impact of Covid-19
 14.3 Key Players
 14.4 Key Market Trends, Growth Factors and Opportunities
 14.4 Historic and Forecasted Market Size By Type
  14.4.1 Branded
  14.4.2 Generics
 14.5 Historic and Forecasted Market Size By Application
  14.5.1 Influenza
  14.5.2 HIV
  14.5.3 Hepatitis
  14.5.4 Herpes Simplex Virus {HSV}
  14.5.5 Coronavirus Infection
  14.5.6 Human Papillomavirus
  14.5.7 Others
 14.6 Historic and Forecasted Market Size By Age Group
  14.6.1 Adult
  14.6.2 Pediatric
 14.7 Historic and Forecasted Market Size By Mechanism of Action
  14.7.1 DNA Polymerase Inhibitors
  14.7.2 Reverse Transcriptase Inhibitors
  14.7.3 Protease Inhibitors
  14.7.4 Neuraminidase Inhibitors
  14.7.5 Integrase inhibitors
  14.7.6 Attachment inhibitors
  14.7.7 Others
 14.8 Historic and Forecast Market Size by Country
  14.8.1 Turkey
  14.8.2 Saudi Arabia
  14.8.3 Iran
  14.8.4 UAE
  14.8.5 Africa
  14.8.6 Rest of MEA

Chapter 15: South America Antiviral Drugs Market Analysis, Insights and Forecast, 2016-2028
 15.1 Key Market Trends, Growth Factors and Opportunities
 15.2 Impact of Covid-19
 15.3 Key Players
 15.4 Key Market Trends, Growth Factors and Opportunities
 15.4 Historic and Forecasted Market Size By Type
  15.4.1 Branded
  15.4.2 Generics
 15.5 Historic and Forecasted Market Size By Application
  15.5.1 Influenza
  15.5.2 HIV
  15.5.3 Hepatitis
  15.5.4 Herpes Simplex Virus {HSV}
  15.5.5 Coronavirus Infection
  15.5.6 Human Papillomavirus
  15.5.7 Others
 15.6 Historic and Forecasted Market Size By Age Group
  15.6.1 Adult
  15.6.2 Pediatric
 15.7 Historic and Forecasted Market Size By Mechanism of Action
  15.7.1 DNA Polymerase Inhibitors
  15.7.2 Reverse Transcriptase Inhibitors
  15.7.3 Protease Inhibitors
  15.7.4 Neuraminidase Inhibitors
  15.7.5 Integrase inhibitors
  15.7.6 Attachment inhibitors
  15.7.7 Others
 15.8 Historic and Forecast Market Size by Country
  15.8.1 Brazil
  15.8.2 Argentina
  15.8.3 Rest of SA

Chapter 16 Investment Analysis

Chapter 17 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. ANTIVIRAL DRUGS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. ANTIVIRAL DRUGS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. ANTIVIRAL DRUGS MARKET COMPETITIVE RIVALRY
TABLE 005. ANTIVIRAL DRUGS MARKET THREAT OF NEW ENTRANTS
TABLE 006. ANTIVIRAL DRUGS MARKET THREAT OF SUBSTITUTES
TABLE 007. ANTIVIRAL DRUGS MARKET BY TYPE
TABLE 008. BRANDED MARKET OVERVIEW (2016-2028)
TABLE 009. GENERICS MARKET OVERVIEW (2016-2028)
TABLE 010. ANTIVIRAL DRUGS MARKET BY APPLICATION
TABLE 011. INFLUENZA MARKET OVERVIEW (2016-2028)
TABLE 012. HIV MARKET OVERVIEW (2016-2028)
TABLE 013. HEPATITIS MARKET OVERVIEW (2016-2028)
TABLE 014. HERPES SIMPLEX VIRUS {HSV} MARKET OVERVIEW (2016-2028)
TABLE 015. CORONAVIRUS INFECTION MARKET OVERVIEW (2016-2028)
TABLE 016. HUMAN PAPILLOMAVIRUS MARKET OVERVIEW (2016-2028)
TABLE 017. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 018. ANTIVIRAL DRUGS MARKET BY AGE GROUP
TABLE 019. ADULT MARKET OVERVIEW (2016-2028)
TABLE 020. PEDIATRIC MARKET OVERVIEW (2016-2028)
TABLE 021. ANTIVIRAL DRUGS MARKET BY MECHANISM OF ACTION
TABLE 022. DNA POLYMERASE INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 023. REVERSE TRANSCRIPTASE INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 024. PROTEASE INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 025. NEURAMINIDASE INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 026. INTEGRASE INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 027. ATTACHMENT INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 028. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 029. NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY TYPE (2016-2028)
TABLE 030. NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 031. NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY AGE GROUP (2016-2028)
TABLE 032. NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY MECHANISM OF ACTION (2016-2028)
TABLE 033. N ANTIVIRAL DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 034. EUROPE ANTIVIRAL DRUGS MARKET, BY TYPE (2016-2028)
TABLE 035. EUROPE ANTIVIRAL DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 036. EUROPE ANTIVIRAL DRUGS MARKET, BY AGE GROUP (2016-2028)
TABLE 037. EUROPE ANTIVIRAL DRUGS MARKET, BY MECHANISM OF ACTION (2016-2028)
TABLE 038. ANTIVIRAL DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 039. ASIA PACIFIC ANTIVIRAL DRUGS MARKET, BY TYPE (2016-2028)
TABLE 040. ASIA PACIFIC ANTIVIRAL DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 041. ASIA PACIFIC ANTIVIRAL DRUGS MARKET, BY AGE GROUP (2016-2028)
TABLE 042. ASIA PACIFIC ANTIVIRAL DRUGS MARKET, BY MECHANISM OF ACTION (2016-2028)
TABLE 043. ANTIVIRAL DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 044. MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET, BY TYPE (2016-2028)
TABLE 045. MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 046. MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET, BY AGE GROUP (2016-2028)
TABLE 047. MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET, BY MECHANISM OF ACTION (2016-2028)
TABLE 048. ANTIVIRAL DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 049. SOUTH AMERICA ANTIVIRAL DRUGS MARKET, BY TYPE (2016-2028)
TABLE 050. SOUTH AMERICA ANTIVIRAL DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 051. SOUTH AMERICA ANTIVIRAL DRUGS MARKET, BY AGE GROUP (2016-2028)
TABLE 052. SOUTH AMERICA ANTIVIRAL DRUGS MARKET, BY MECHANISM OF ACTION (2016-2028)
TABLE 053. ANTIVIRAL DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 054. GILEAD SCIENCES INC: SNAPSHOT
TABLE 055. GILEAD SCIENCES INC: BUSINESS PERFORMANCE
TABLE 056. GILEAD SCIENCES INC: PRODUCT PORTFOLIO
TABLE 057. GILEAD SCIENCES INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 057. GLAXOSMITHKLINE PLC: SNAPSHOT
TABLE 058. GLAXOSMITHKLINE PLC: BUSINESS PERFORMANCE
TABLE 059. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 060. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 060. JOHNSON & JOHNSON SERVICES INC: SNAPSHOT
TABLE 061. JOHNSON & JOHNSON SERVICES INC: BUSINESS PERFORMANCE
TABLE 062. JOHNSON & JOHNSON SERVICES INC: PRODUCT PORTFOLIO
TABLE 063. JOHNSON & JOHNSON SERVICES INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 063. ASTRAZENECA: SNAPSHOT
TABLE 064. ASTRAZENECA: BUSINESS PERFORMANCE
TABLE 065. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 066. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 066. ABBVIE INC: SNAPSHOT
TABLE 067. ABBVIE INC: BUSINESS PERFORMANCE
TABLE 068. ABBVIE INC: PRODUCT PORTFOLIO
TABLE 069. ABBVIE INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 069. MERCK & CO INC: SNAPSHOT
TABLE 070. MERCK & CO INC: BUSINESS PERFORMANCE
TABLE 071. MERCK & CO INC: PRODUCT PORTFOLIO
TABLE 072. MERCK & CO INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 072. TEVA PHARMACEUTICAL INDUSTRIES LTD: SNAPSHOT
TABLE 073. TEVA PHARMACEUTICAL INDUSTRIES LTD: BUSINESS PERFORMANCE
TABLE 074. TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
TABLE 075. TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 075. REGENERON PHARMACEUTICALS INC: SNAPSHOT
TABLE 076. REGENERON PHARMACEUTICALS INC: BUSINESS PERFORMANCE
TABLE 077. REGENERON PHARMACEUTICALS INC: PRODUCT PORTFOLIO
TABLE 078. REGENERON PHARMACEUTICALS INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 078. BRISTOL-MYERS SQUIBB COMPANY: SNAPSHOT
TABLE 079. BRISTOL-MYERS SQUIBB COMPANY: BUSINESS PERFORMANCE
TABLE 080. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 081. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 081. ZYDUS CADILA: SNAPSHOT
TABLE 082. ZYDUS CADILA: BUSINESS PERFORMANCE
TABLE 083. ZYDUS CADILA: PRODUCT PORTFOLIO
TABLE 084. ZYDUS CADILA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 084. CIPLA INC: SNAPSHOT
TABLE 085. CIPLA INC: BUSINESS PERFORMANCE
TABLE 086. CIPLA INC: PRODUCT PORTFOLIO
TABLE 087. CIPLA INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 087. PRINSTON PHARMACEUTICAL INC: SNAPSHOT
TABLE 088. PRINSTON PHARMACEUTICAL INC: BUSINESS PERFORMANCE
TABLE 089. PRINSTON PHARMACEUTICAL INC: PRODUCT PORTFOLIO
TABLE 090. PRINSTON PHARMACEUTICAL INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 090. HETERO: SNAPSHOT
TABLE 091. HETERO: BUSINESS PERFORMANCE
TABLE 092. HETERO: PRODUCT PORTFOLIO
TABLE 093. HETERO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 093. AUROBINDO PHARMA: SNAPSHOT
TABLE 094. AUROBINDO PHARMA: BUSINESS PERFORMANCE
TABLE 095. AUROBINDO PHARMA: PRODUCT PORTFOLIO
TABLE 096. AUROBINDO PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 096. APOTEX INC: SNAPSHOT
TABLE 097. APOTEX INC: BUSINESS PERFORMANCE
TABLE 098. APOTEX INC: PRODUCT PORTFOLIO
TABLE 099. APOTEX INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 099. MYLAN N.V.: SNAPSHOT
TABLE 100. MYLAN N.V.: BUSINESS PERFORMANCE
TABLE 101. MYLAN N.V.: PRODUCT PORTFOLIO
TABLE 102. MYLAN N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 102. VIR BIOTECHNOLOGY INC.: SNAPSHOT
TABLE 103. VIR BIOTECHNOLOGY INC.: BUSINESS PERFORMANCE
TABLE 104. VIR BIOTECHNOLOGY INC.: PRODUCT PORTFOLIO
TABLE 105. VIR BIOTECHNOLOGY INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 105. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 106. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 107. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 108. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. ANTIVIRAL DRUGS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. ANTIVIRAL DRUGS MARKET OVERVIEW BY TYPE
FIGURE 012. BRANDED MARKET OVERVIEW (2016-2028)
FIGURE 013. GENERICS MARKET OVERVIEW (2016-2028)
FIGURE 014. ANTIVIRAL DRUGS MARKET OVERVIEW BY APPLICATION
FIGURE 015. INFLUENZA MARKET OVERVIEW (2016-2028)
FIGURE 016. HIV MARKET OVERVIEW (2016-2028)
FIGURE 017. HEPATITIS MARKET OVERVIEW (2016-2028)
FIGURE 018. HERPES SIMPLEX VIRUS {HSV} MARKET OVERVIEW (2016-2028)
FIGURE 019. CORONAVIRUS INFECTION MARKET OVERVIEW (2016-2028)
FIGURE 020. HUMAN PAPILLOMAVIRUS MARKET OVERVIEW (2016-2028)
FIGURE 021. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 022. ANTIVIRAL DRUGS MARKET OVERVIEW BY AGE GROUP
FIGURE 023. ADULT MARKET OVERVIEW (2016-2028)
FIGURE 024. PEDIATRIC MARKET OVERVIEW (2016-2028)
FIGURE 025. ANTIVIRAL DRUGS MARKET OVERVIEW BY MECHANISM OF ACTION
FIGURE 026. DNA POLYMERASE INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 027. REVERSE TRANSCRIPTASE INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 028. PROTEASE INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 029. NEURAMINIDASE INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 030. INTEGRASE INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 031. ATTACHMENT INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 032. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 033. NORTH AMERICA ANTIVIRAL DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 034. EUROPE ANTIVIRAL DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 035. ASIA PACIFIC ANTIVIRAL DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 036. MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 037. SOUTH AMERICA ANTIVIRAL DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)